KB-1649

Dalmitamig

49265

Home » Dalmitamig

Background of Dalmitamig

Dalmitamig (REGN7075), a first-in-class costimulatory bispecific antibody (bsAb), aims to restore immune sensitivity in traditionally non-immunoresponsive tumors by bridging CD28+ T cells with EGFR-expressing tumor cells (unlike other bsAbs that target CD3), facilitating T-cell activation through endogenous tumor antigens.

Specifications

Catalog Number	KB-1649
Antibody Name	Dalmitamig
Isotype	Human IgG4
FC Muations	CD28 HC: S228P/E233P/F234AV/L235Del/G236A/H435R/Y436F/L445P EGFR HC: S228P/E233P/F234AV/L235Del/G236A
Target	EGFRxCD28
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C;Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Neil Howard Segal et al., A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results.. JCO 42, 2503-2503(2024).
WO2020198009 - EGFR x CD28 MULTISPECIFIC ANTIBODIES